Obtenga las últimas noticias sobre las acciones de Scholar Rock Holding con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de SRRK

Últimas noticias sobre

SCHOLAR ROCK HOLDING CORP

Scholar Rock Holding

Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.

ACTU

ALVO

BACK

CSBR

EVGR

GLRE

HEPA

JDZG

JYNT

LUNG

PRTA

SRRK

UNTY

VREX

YIBO

ZKIN

IMAC Holdings sube más del 108% tras anunciar Ignite Proteomics. Conoce las acciones más destacadas en la negociación previa.

Acciones de IMAC Holdings se disparan un 108%; 20 acciones en movimiento en el premercado de EE.UU.

Scholar Rock Holding Corporation - Common Stock

Scholar Rock Holding Corp

Press Releases

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss

Scholar Rock to Present Comprehensive Update at 2025 Annual Cure SMA Research and Clinical Care Meeting, Including Positive Results from Pivotal Phase 3 SAPPHIRE Trial

Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025

Scholar Rock Reports Second Quarter 2025 Financial Results and Highlights Business Progress

Pivotal SAPPHIRE Trial Data Published in The Lancet Neurology: Apitegromab Demonstrated Significant Motor Function Gains for Children and Adults with SMA on SMN-Targeted Treatment

FDA Issues Complete Response Letter (CRL) for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) Solely Related to Observations Identified at Catalent Indiana LLC Fill-Finish Facility

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

Alvotech

Apellis Pharmaceuticals, Inc. - Common Stock

Apellis Pharmaceuticals

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Beam Therapeutics

Cidara Therapeutics

CG Oncology

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Catalyst Pharmaceuticals, Inc. - Common Stock

Catalyst Pharmaceuticals

Denali Therapeutics

Amicus Therapeutics

GRAIL

IDEAYA Biosciences

Immunovant

Disc Medicine

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Ultragenyx Pharmaceutical Inc. - Common Stock

Ultragenyx Pharmaceutical

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Veracyte

Xenon Pharmaceuticals Inc. - Common Shares

Xenon Pharmaceuticals

Zai Lab Limited - American Depositary Shares

Comments

Scholar Rock Holding Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL